These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. One-year experience with intravenous treprostinil for pulmonary arterial hypertension. Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV. J Heart Lung Transplant; 2013 Sep 15; 32(9):889-96. PubMed ID: 23953817 [Abstract] [Full Text] [Related]
9. Treprostinil for pulmonary hypertension. Skoro-Sajer N, Lang I, Naeije R. Vasc Health Risk Manag; 2008 Sep 15; 4(3):507-13. PubMed ID: 18827901 [Abstract] [Full Text] [Related]
11. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. LeVarge BL, Channick RN. Expert Rev Respir Med; 2012 Jun 15; 6(3):255-65. PubMed ID: 22788940 [Abstract] [Full Text] [Related]
12. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Minai OA, Parambil J, Dweik RA, Davila GH, Peterson L, Rollins KD, Chen H. Respir Med; 2013 Mar 15; 107(3):458-65. PubMed ID: 23266038 [Abstract] [Full Text] [Related]
13. Oral treprostinil diethanolamine for pulmonary arterial hypertension. Feldman J, Im Y, Gill K. Expert Rev Clin Pharmacol; 2015 Jan 15; 8(1):55-60. PubMed ID: 25409915 [Abstract] [Full Text] [Related]
14. The role of treprostinil in the management of pulmonary hypertension. Skoro-Sajer N, Lang I. Am J Cardiovasc Drugs; 2008 Jan 15; 8(4):213-7. PubMed ID: 18690755 [Abstract] [Full Text] [Related]
15. Cost effectiveness of prostacyclins in pulmonary arterial hypertension. Roman A, Barberà JA, Escribano P, Sala ML, Febrer L, Oyagüez I, Sabater E, Casado MA. Appl Health Econ Health Policy; 2012 May 01; 10(3):175-88. PubMed ID: 22452448 [Abstract] [Full Text] [Related]
16. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Rich JD, Glassner C, Wade M, Coslet S, Arneson C, Doran A, Gomberg-Maitland M. Chest; 2012 Jan 01; 141(1):36-42. PubMed ID: 21659437 [Abstract] [Full Text] [Related]
17. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Rubenfire M, McLaughlin VV, Allen RP, Elliott G, Park MH, Wade M, Schilz R. Chest; 2007 Sep 01; 132(3):757-63. PubMed ID: 17400684 [Abstract] [Full Text] [Related]
18. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. Gessler T, Seeger W, Schmehl T. Ther Adv Respir Dis; 2011 Jun 01; 5(3):195-206. PubMed ID: 21300738 [Abstract] [Full Text] [Related]